Relationship of transforming growth factor beta 1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma. by Walker, R. A. et al.
Br. J. Cancer (1994), 69, 1160 1165 © Macmillan Press Ltd.,
Relationship of transforming growth factor P3 to extracellular matrix and
stromal infiltrates in invasive breast carcinoma
R.A. Walker, S.J. Dearing & B. Gallacher
Breast Cancer Research Unit, University of Leicester, Clinical Sciences, Glenfield General Hospital, Groby Road, Leicester
LE3 9QP, UK.
Summary Transforming growth factor P (TGF-P) comprises a group of multifunctional regulatory proteins,
whose effects include stimulation of extracellular matrix formation and modification of immune function. The
presence ofTGF-P, and TGF-P2 in invasive breast carcinomas has been determined and related to pathological
features, the presence of fibronectin and tenascin and lymphocyte/macrophage infiltration, using immunohisto-
chemistry. Differences were observed in the extent of reactivity within the same carcinoma and between
tumours stained with an antibody detecting TGF-P, and one detecting TGF-P, plus TGF-132, the latter having
a higher level of reactivity. Prominent reactivity for TGF-P, was associated with lymph node metastasis,
(0.02>P> 0.01), increased detection of cellular fibronectin, fine stromal fibronectin staining, more prominent
reactivity for tenascin (0.02> P> 0.01), the presence of tumour-associated macrophage infiltration and altered
ratios of CD4 and CD8 lymphocyte populations, with CD8 lymphocytes predominating. These associations
were not observed for carcinomas showing prominent staining with antibody detecting TGF-P2 as well as
TGF-p,. The findings indicate that TGF-P, may have a role in invasion and metastasis of breast carcinomas.
Transforming growth factor , (TGF-,B) comprises a group of
multifunctional regulatory proteins which have many effects
on physiological and pathological processes (Roberts et al.,
1988). To date five TGF-P isotypes have been recognised:
TGF-p3, TGF-P2 and TGF-P3 are found in mammalian tis-
sues (Derynck et al., 1985, 1988; de Martin et al., 1987),
TGF-P4 in avian (Jakowlew et al., 1988) and TGF-P5 in
Xenopus (Kondaiah et al., 1990). The mature forms of TGF-
PI, A and -A show 70-80% homology at the amino acid
level.
TGF-P can both stimulate and inhibit cell proliferation,
the effect depending on the type of cell involved. It can block
or effect entry into differentiation pathways. Extracellular
matrix formation can be stimulated and cell migration either
promoted or inhibited (Barnard et al., 1990). The promotion
of extracellular matrix formation is effected by several
mechanisms: stimulation of synthesis of type I collagen and
fibronectin (Ignotz & Massague, 1986) and tenascin (Pearson
et al., 1988); inhibition of proteinase synthesis and stimula-
tion of proteinase inhibitor synthesis (Edwards et al., 1987).
TGF-P also has effects on immune function, suppressing the
growth of T and B lymphocytes (Kehrl et al., 1986a and b)
and modifying the function of macrophages (Tsunawaki et
al., 1988).
The stroma of carcinomas differs from that of comparable
normal organs and is believed to be an important factor in
malignant growth (Van der Hooff, 1988). Abundant fibronec-
tin can be identified in the stroma of many breast car-
cinomas, and the pattern of distribution correlates with
metastatic potential (Christensen et al., 1989). Tenascin is
also highly expressed in the stroma of malignant but not
benign breast tumours (Mackie et al., 1987). The breast
cancer cell line MCF-7 reacts to exogenous tenascin by adop-
ting an invasive phenotype, losing cell-cell and
cell-substrate contacts (Chiquet-Ehrismann et al., 1989). The
pattern and extent of lymphocyte and macrophage infiltrate
in breast carcinomas may be of significance in relation to
tumour behaviour (Vose & Moore, 1985). We have
previously identified an association between high numbers of
activated macrophages in breast cancers and lymph node
metastasis (Zuk & Walker, 1987).
In a previous immunohistochemical study ofTGF-p3, in in
situ and invasive breast carcinomas, a significant difference
was noted, with fewer in situ carcinomas having detectable
TGF-P3 (Walker & Dearing, 1992). This suggested that TGF-
P may play a role in invasion. The present study has con-
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sidered TGF-P in invasive carcinomas in relation to stromal
components, lymphocyte/macrophage infiltrates and tumour
characteristics to consider further the potential role ofTGF-P
in invasion and metastasis.
Materials and methods
Tissues
Tissue from 86 invasive breast carcinomas were studied. All
specimens had been received fresh immediately after surgery
and samples frozen in liquid nitrogen with a parallel block
fixed in 4% formaldehyde in saline for 18-36 h prior to
processing through paraffin wax.
Antibodies
Two antibodies directed against TGF-P were used. One was
an affinity-purified polyclonal antiserum to TGF-P1 (a gift
from Professor Marc Feldmann, Sunley Research Centre,
Charing Cross, London, UK). It had been raised against
human TGF-pl, and specificity for TGF-P1 but not for A2 or
A had been confirmed by enzyme-linked immunoabsorbent
assay (ELISA) immunoprecipitation and Western blotting
(Chantry et al., 1989). The other antibody was obtained from
Genzyme and was a mouse monoclonal. It had been raised
against bovine TGF-132 and recognised bovine and human
TGF-P3 and TGF-P2 as well as Xenopus TGF-P2 and chick
TGF-P3.
Monoclonal antibodies to human fibronectin (clone FN-
15) and cellular fibronectin (FN-3E2) were from Sigma. The
human fibronectin antibody was raised against fibronectin
from human plasma; specificity had been confirmed by
ELISA and Western blotting. The cellular fibronectin
antibody was raised against fibronectin released from a
breast cancer cell line and localised to the 240 kDa band of
cellular fibronectin on Western blotting. The monoclonal
antibody to tenascin (clone EB2) was raised against purified
tenascin from fetal fibroblasts and was obtained from ICN.
On Western blotting it reacts with tenascin polypeptides of
250 and 180 kDa.
Two CD68 monoclonal antibodies against human macro-
phages, PGM1 and EBM11 (Dako), were used. For T-
lymphocyte detection the monoclonal antibodies (UCHTI
(CD3) MT310 (CD4) and DK25 (CD8) (all Dako) were
employed, with Tol5 (pan-B) (Dako) monoclonal antibody
for B-lymphocyte detection.
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Immunohistochemistry
Formalin-fixed, paraffin-embedded sections were used for the
detection of TGF-1, fibronectin and macrophages using
PGM1. Frozen sections were used for the detection of tenas-
cin, T and B lymphocytes and macrophages using EBM11.
The antiserum to TGF-P1, was applied to 58 carcinomas at
a concentration of 3.6 1sg ml-' for 18 h at 4°C. After rinsing
and washing in Tris-buffered saline, biotinylated swine anti-
rabbit immunoglobulin serum was applied, followed by strep-
tavidin-biotin-peroxidase complex. The peroxidase was
developed using diaminobenzidene-hydrogen peroxide. Pre-
immune rabbit serum was used as a control. The antibody
against TGF-P, and TGF-P2 was applied to 38 carcinomas,
ten ofwhich had been assessed with the TGF-P, antiserum. It
was used at a 1:20 dilution with incubation for 18 h at 4°C.
The same technique was used, but with a biotinylated rabbit
anti-mouse immunoglobulin serum.
For the detection offibronectin sections were digested with
0.025% pepsin (Sigma) in 0.01 M hydrochloric acid at 37°C
for 45 min prior to the application of both antibodies. These
were used at 1:50 dilution with the same technique as above.
For the detection of macrophages in formalin-fixed, paraffin-
embedded sections, digestion with 0.1% trypsin pH 7.8 for
20 min at 37°C was used with PGM1 at 1:100 dilution, and
the streptavidin-biotin technique.
All frozen sections were fixed in cold acetone for Omin
prior to the application of the primary antibodies as des-
cribed previously (Zuk & Walker, 1987; Jones et al., 1992).
Sufficient frozen material for the detection of CD4 and CD8
lymphocytes was available for 80 cases and for tenascin for
71 cases. The streptavidin-biotin complex technique was
used throughout. Controls in all instances were the omission
of the primary antibody.
Clinicopathologicalfeatures
Haematoxylin and eosin-stained sections of all carcinomas
were assessed for type and for histological grade, using the
modified Bloom and Richardson system (Elston, 1987).
Lymph node status was known for 75 cases.
Statistical analysis was by chi-square or Fisher's exact test.
Results
TGF-P reactivity
The staining of the carcinomas was classified as negative;
having less than 10% positive cells; between 10 and 50%
positive cells; and more than 50% positive cells. Differences
were observed in the extent of reactivity with the two
antibodies. The results are summarised in Table I. Staining of
stroma with occasional staining of fibroblasts but without
reactivity of tumour cells was only observed with the TGF-P1
antiserum. The staining pattern with this antiserum differed
in other respects, in that normal epithelium showed no stain-
ing or very weak reactivity, while tumour cell reactivity was
prominent (Figure 1). This differed from the staining
observed with the antibody detecting TGF-P1, and TGF-132 in
that normal epithelium was reactive, and the staining of
tumour cells was generally of similar intensity. Of the ten
carcinomas stained with both antibodies, four were negative
with TGF-1, antibody but had 10-50% positive cells with
the antibody against TGF-P, and TGF-P2 (Figure 2), four
Table I Comparison of the extent of staining observed in breast
carcinomas with the antibodies against TGF-P, and TGF-P, and A
Reactivity TGF-p, TGF-P, and TGF-P2
Negative 20 (34.5%) 3 (11%)
Stromal only 7 (12%) 0
< 10% positive cells 10 (17.25%) 7 (25%)
10-50% positive cells 10 (17.25%) 9 (32%)
>50% positive cells 11(19%) 9 (32%)
Figure 1 Infiltrating ductal carcinoma showing prominent stain-
ing for TGF-P, protein.
had less than 10% cells positive for TGF-P, but between 10
and 50% positive for TGF-P, and -P2, and two had between
10 and 50% cells positive with TGF-j, antibody but more
than 50% cells staining with the antibody against TGF-P,
and TGF-P2.
Apart from the small number of cases with stromal stain-
ing in which there was fibroblast reactivity, there was no
staining of stromal cells such as macrophages.
Relationship to clinicopathologicalparameters
Seventy-five of the carcinomas were infiltrating ductal and 11
infiltrating lobular carcinomas. No differences were observed
between the two categories with either antibody. There were
ten well-differentiated carcinomas, 44 moderately differen-
tiated and 32 poorly differentiated carcinomas. There was no
relationship between staining and histological grade for either
antibody.
Forty-five carcinomas had metastasised to lymph nodes
and 30 had not. All of the carcinomas with > 50% of cells
positive for TGF-,B had metastasised, which was significant
(0.02>P>0.01). The distribution of node-positive and
-negative cases for the other staining categories of TGF-1,
was as expected, as was the distribution for all staining
categories for TGF-PI, and A-
Relationship with stromal components
Cellular fibronectin was detected in tumour cells in 30 (35%)
carcinomas (Figure 3). The extent of reactivity ranged from
10% to 80% of cells being positive, with associated lesser
stromal reactivity. The other fibronectin antibody detected
the stromal component, with cellular staining being seen
much less frequently. The pattern of staining was pre-
dominantly of coarse bands, but in 13 carcinomas only fine
irregular stromal staining was seen, and in a further 13 both
coarse and fine stromal staining was observed. The com-
parison between fibronectin reactivity and staining for TGF-P
is shown in Table II. The presence of cellular fibronectin was
greater in those cases with more prominent reactivity for
TGF-P, and TGF-P, plus TGF-P2. A greater degree of fine
stromal reactivity for fibronectin was seen in cases with more
prominent reactivity for TGF-1,B.1162 R.A. WALKER et al.
a The extent of staining for tenascin was subdivided into
marked (+++ +), moderate (+ +) or scanty (+), as des-
cribed previously (Jones et al., 1992) (Figure 4). Marked
reactivity was seen in 31 carcinomas, moderate in 29 and
scanty in 11. The degree of staining in comparison with
TGF-P reactivity is shown in Table III. Marked reactivity for
tenascin was seen in almost all carcinomas with prominent
staining for TGF-pl, and was significant (0.02>P>0.01),
but no relationship was observed for staining with the
antibody against TGF-P1 and TGF-P2.
Relationship with macrophage/lymphocytic infiltration
There was generally a greater number of cells staining in the
frozen sections incubated with EBM 11 than the fixed sec-
tions reacted with PGM1, and in all cases the higher level of
macrophage staining was taken for comparisons. Macro-
phages were seen either within the stroma or within and
closely abutting tumour cell groups, subsequently called
tumour associated. The extent of macrophage infiltration and
whether it was stromal and/or tumour associated were
related to the degree of TGF-P reactivity within carcinomas.
The extent of reactivity did not relate to TGF-P staining.
Stromal macrophage reactivity only was seen in 35 car-
cinomas (41%), with stromal macrophage numbers being
greater than tumour associated in 16 tumours (18.5%). In 25
carcinomas (29%) there was equal reactivity for stromal and
tumour-associated macrophages. Only two tumours had
b
Figure 2 a, Infiltrating ductal carcinoma showing no reactivity
with antibody against TGF-pj. b, Serial section of the same
carcinoma showing staining of tumour cells with antibody against
TGF-P, and TGF-P2.
Figure 3 Infiltrating ductal carcinoma with many tumour cells
showing staining for cellular fibronectin.
Table II The pattern and/or extent ofreactivity ofstromal components in relation to the extent ofstaining forTGF-P obtained
with the two antibodies (n = number postive/total)
TGF-P Cellularfibronectin Coarse stromalfibronectin Fine stromalfibronectin
reactivity TGF-p1 TGF-P, + TGF-P2 TGF-P, TGF-P, + TGF-P12 TGF-p1 TGF-P, + TGF-132
Negative 6/20 0/3 15/20 1/3 5/20 1/3
Stromal only 1/7 0 4/7 0 3/7 0
< 10% 2/10 0/7 3/10 4/7 3/10 1/7
10-50% 4/10 3/9 4/10 7/9 6/10 2/9
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Table III Extent of tenascin reactivity in comparison with TGF-P staining
TGF-P Marked tenascin Moderate tenascin Scanty tenascin
reactivity TGF-P3 TGF-P1, + -P2 TGF-P, TGF-P1 + -P2 TGF-P1 TGF-j, + -Pi2
Negative 5/17 1/3 6/17 1/3 6/17 1/3
Stromal only 3/6 0 3/6 0 0/6 0
< 10% 1/8 3/6 5/8 3/6 2/8 0/6
10-50% 3/6 5/9 3/6 4/9 0/6 0/9
> 50% 8/9 2/7 1/9 3/7 0/9 2/7
Figure 4 a, Frozen section of carcinoma showing prominent
staining for tenascin. b, Minimal reactivity for tenascin in frozen
section of another infiltrating ductal carcinoma.
more prominent tumour-associated macrophage staining, and
eight carcinomas had this as the only pattern of macrophage
staining. Stromal macrophage staining only or greater
stromal macrophage reactivity was seen in over half the
carcinomas in each TGF-P staining category apart from
those carcinomas with prominent staining for TGF-,B in
which two showed only stromal staining, two only tumour-
associated macrophage staining and the remaining seven
equal reactivity for stromal and tumour-associated macro-
phages.
B-lymphocyte reactivity was minimal in the majority of
carcinomas studied, and showed no correlation with TGF-P
reactivity. The numbers of T lymphocytes overall varied
between the carcinomas, and this did not relate to TGF-1B
reactivity. The extent of the CD4- and CD8-positive lym-
phocytes did vary and the results are shown in Table IV.
Two-thirds of the carcinomas had a greater number of
CD4-positive lymphocytes than CD8-positive cells, with 16%
having equal numbers and 20% a greater number of CD8-
positive cells. Of those carcinomas with prominent TGF-P3
reactivity, there were two-thirds with greater CD8 reactivity.
Discussion
In a previous immunohistochemical study ofTGF-P (Walker
& Dearing, 1992) we identified a difference in detection of
TGF-P1 between in situ and invasive carcinomas, indicating a
role for TGF-P3 in invasion. The present study has shown
that any relationship between TGF-P and invasion and
metastasis is only found for TGF-1,3 and not for TGF-P2.
This is in keeping with the findings of Gorsch et al. (1992),
who identified a relationship between immunoreactivity for
TGF-1,3 and disease progression in human breast carcinoma.
It also reinforces the view of Arteaga and Coffey (1992),
based on the study of McCune et al. (1992), that it is
important to consider the different isoforms of TGF-P since
they clearly do have different roles.
Because of the availability of antisera the number of cases
which could be examined for TGF-P3 was restricted. Com-
parison of staining in individual cases, and of the extent of
reactivity in other cases, showed that there was greater reac-
tivity using an antibody detecting both TGF-P, and TGF-P2.
Because the results obtained were clearly less significant,
staining with this antibody was not pursued.
Prominent reactivity for TGF-P,B was associated with nodal
metastasis, higher frequency of detection of cellular fibronec-
tin, different patterns of reactivity of stromal fibronectin,
marked tenascin reactivity, higher frequency of macrophage
infiltration being tumour associated and different levels of
CD8 lymphocyte infiltrates in comparison with CD4. The
various correlates were not restricted to tumours with promi-
nent TGF-pl, and not all tumours having that pattern of
TGF-P, reactivity showed them, but there were obvious
associations. Further studies using a monospecific reagent are
needed to consolidate these findings.
Studies of rat mammary adenocarcinoma cells have shown
that exogenous TGF-,B, may modulate the metastatic poten-
tial of mammary tumour cells by controlling their ability to
break down and penetrate basement membrane barriers
(Welch et al., 1990). The TGF-P1 secreted from tumour cells
could have the same effect, providing it is biologically active.
This can only be determined by in vitro assays. Mizoi et al.1164 R.A. WALKER et al.
Table IV The extent ofCD4 and CD8 reactivity in carcinomas in comparison with TGF-P staining, with
both antibodies
TGF-P CD4>CD8 CD4 = CD8 CD8>CD4
reactivity TGF-P, TGF-PI + 42 TGF-I3 TGF-P3 + -P2 TGF-1i3 TGF-P3 + -P2
Negative 13 2 2 0 3 1
Stromal only 3 0 3 0 0 0
<10% 8 3 0 4 1 0
10-50% 6 5 2 2 1 2
>50% 4 7 0 1 7 1
(1993) have demonstrated in gastrointestinal carcinomas that
the precursor form ofTGF-P3 is within the cytosol of tumour
cells, which may suggest blocked transport. Further studies,
preferably dynamic, would be required to determine whether
this is the situation in breast carcinomas.
Differences in stromal and cellular fibronectin were
observed relating to TGF-pl. Previous immunohistochemical
studies of stromal fibronectin have described pericellular
reactivity, particularly at the invasive border, as well as a
diffuse staining pattern (Christensen et al., 1989). Pericellular
staining was rarely seen, the more striking difference in the
present study being the presence of fine stromal staining.
Cytoplasmic fibronectin has previously been reported to be
related to the degree of anaplasia, and more striking in
independently growing breast cancer cells (Christensen et al.,
1985). The other extracellular matrix protein studied, tenas-
cin, was readily identified in the stroma of the breast car-
cinomas, as previously reported (Mackie et al., 1987; Natali
et al., 1991; Jones et al., 1992). Tenascin is induced by
TGF-,B in vitro (Pearson et al., 1988). Tenascin can block the
action of fibronectin (Chiquet-Ehrismann et al., 1988),
inhibiting cell attachment. In vitro addition of tenascin to
MCF-7 breast cancer cell lines results in their loss ofcell-cell
and cell-substrate contacts (Chiquet-Ehrismann et al., 1989).
If the same occurs in primary breast carcinomas in vivo, it
could be proposed that the overexpression of TGF-P1
stimulates synthesis of tenascin, which aids invasion and
hence metastasis.
We were unable to detect TGF-P in macrophages within
the breast carcinomas, although in other sites, such as lung,
macrophages are a source of TGF-P (Assoian et al., 1987).
The main findings related to the presence and relative pro-
portion of tumour-associated macrophages, which were in-
creased in relation to greater TGF-P, expression. In other
tissues TGF-P is a potent chemoattractant for macrophages.
The function ofmacrophages within breast carcinomas could
be as a host defence mechanism or the converse owing to
release of enzymes involved in destruction of basement mem-
branes, so aiding invasion. An association between nodal
metastasis and macrophage infiltration has been observed
(Zuk & Walker, 1987).
No differences were found in the numbers of B and T
lymphocytes in relation to TGF-P reactivity, but an altera-
tion in the ratio of CD4 to CD8 cells was seen. As in a
previous study (Zuk & Walker, 1987) CD4 lymphocytes
predominated in many of the carcinomas, apart from those
with prominent TGF-P1 reactivity. Naukkarinen and Syr-
janen (1990) identified an association between CD8 lym-
phocytic infiltration and post-capillary venule endothelium in
breast carcinomas. TGF-P3 has a role in angiogenesis and
may account for this association.
Prominent expression of TGF-P, but not TGF-P2 is
therefore associated with changes in the extracellular matrix
and in stromal infiltrates in breast carcinomas, which in view
of the previously identified differences between in situ and
invasive carcinoma and the higher frequency of nodal meta-
stasis points to a role for TGF-P1 in invasion and metastasis.
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